Equities

OXB

OXB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)412.50
  • Today's Change-4.50 / -1.08%
  • Shares traded130.45k
  • 1 Year change+93.66%
  • Beta1.5924
Data delayed at least 20 minutes, as of Nov 08 2024 16:39 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. It provides viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers several technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. It has bioprocessing and manufacturing facilities across Oxfordshire, United Kingdom, Lyon and Strasbourg, France and near Boston, MA, United Sates. Its Platform segment is involved in bioprocessing and process development activities undertaken for third parties. Its Viral Vector includes LentiVector platform, inAAVate platform, and Other Viral Vectors. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system.

  • Revenue in GBP (TTM)97.28m
  • Net income in GBP-142.02m
  • Incorporated1996
  • Employees834.00
  • Location
    OXBWindrush Court, Transport WayOXFORD OX4 6LTUnited KingdomGBR
  • Phone+44 186 578 3000
  • Fax+44 186 578 3001
  • Websitehttps://www.oxb.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Futura Medical PLC8.40m-3.75m116.70m12.00--14.85--13.90-0.0126-0.01260.02720.02590.85385,710.277.20699,850.80-38.14-79.25-47.43-127.2267.70---44.68-914.373.75--0.00-------11.40--219.68--
Scancell Holdings Plc0.00-5.86m127.82m61.00---------0.0068-0.00680.00-0.00380.00----0.00-23.24-31.66-32.48-37.66-------822.37----1.21---100.00--50.91--131.54--
Faron Pharmaceuticals Oy0.00-26.22m159.08m34.00--139.07-----0.3151-0.31510.000.01090.00----0.00-130.90-213.06-443.92-963.12-----------5.990.9022-------7.71---16.05--
4Basebio PLC596.00k-9.84m163.34m--------274.06-0.7843-0.78430.0476-0.40750.05080.645310.64---83.78---97.43--69.63---1,650.67--2.53-18.441.51--88.81---48.83------
Avacta Group Plc22.62m-25.89m180.96m154.00--3.67--8.00-0.0867-0.08670.0750.13340.25554.633.15146,876.60-29.24---61.16--42.08---114.45--1.21-1.230.3875--140.83--32.54------
hVIVO PLC64.38m17.45m185.74m274.0010.824.838.992.880.02520.02520.09320.05650.9242--4.25234,974.5025.04-0.64346.68-1.29----27.10-0.7651.60--0.2530--15.6135.402,176.68--136.55--
Bioventix PLC13.61m8.10m193.13m16.0024.2116.0923.5214.191.531.532.572.301.011.572.26--59.9558.3367.2463.6293.2093.0959.5164.127.07----90.926.177.93-3.296.67-28.4016.25
Allergy Therapeutics plc53.26m-50.22m257.39m635.00--9.73--4.83-0.0266-0.02660.0170.00560.75712.214.9283,870.87-71.39-11.59-102.10-15.1552.5470.08-94.29-11.780.9281-7.930.2713---18.11-2.71-212.65--16.41--
Puretech Health PLC362.20k-63.82m377.30m90.00--1.54--1,041.69-0.2328-0.23280.00131.020.0007--0.22524,024.44-14.134.92-16.355.94-----19,222.22352.67----0.07280.00-78.68-30.64-30.47---44.10--
Oxford BioMedica plc97.28m-142.02m436.93m834.00--6.56--4.49-1.44-1.440.96420.62920.30124.094.21136,252.10-51.98-19.60-66.85-24.6836.7450.74-172.59-44.382.07-12.470.6077---36.046.04-302.20---0.6307--
Genus plc668.80m7.90m1.23bn3.44k156.802.2424.861.840.11860.118610.148.300.6569--5.84194,475.100.23573.300.27423.87----0.35894.981.2193.170.348762.72-3.036.48-76.280.2551-2.682.93
Data as of Nov 08 2024. Currency figures normalised to OXB's reporting currency: UK Pound GBX

Institutional shareholders

36.57%Per cent of shares held by top holders
HolderShares% Held
Vulpes Investment Management Pte Ltd.as of 23 Oct 20238.44m8.01%
Liontrust Investment Partners LLPas of 29 Oct 20245.27m5.00%
M&G Investment Management Ltd.as of 15 Mar 20235.07m4.81%
Global Alpha Capital Management Ltd.as of 15 Mar 20233.88m3.68%
BlackRock Investment Management (UK) Ltd.as of 01 Oct 20243.64m3.46%
Hargreaves Lansdown Asset Management Ltd.as of 15 Mar 20233.03m2.88%
Charles Schwab Investment Management, Inc.as of 03 Sep 20243.01m2.86%
The Vanguard Group, Inc.as of 15 Mar 20232.71m2.57%
Banque Pictet & Cie SAas of 03 Sep 20241.92m1.82%
Threadneedle Asset Management Ltd.as of 03 Sep 20241.56m1.48%
More ▼
Data from 11 Apr 2024 - 09 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.